Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Netherlands Cancer Institute
In locally advanced NSCLC local control has been poor, but with SABR remarkable high local control rates with low toxicity have been reported. Currently stage III and inoperable II NSCLC patients have been treated with IMRT and concurrent chemotherapy at out institute. In this study we will explore the combination of SABR and CFRT with concurrent chemotherapy
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may not be if
Weight loss \< 10% in the last three months
WHO-performance status ≤ 2
Patients that receive concurrent chemoradiotherapy, with the exception of adriamycin and gemcitabine
FEV1 and DLCO \> 40 % of the age-adjusted normal value
Minimum required laboratory data bone marrow reserve and hepatic- and renal function
Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Before patient registration, written informed consent must be given according to GCP and national regulations
Patients with central tumors \< 2 cm of the proximal bronchial tree (Figure 2) or tumors immediately adjacent to mediastinal or pericardial pleura.
Patients that receive sequential chemoradiotherapy or radiotherapy only.
Patients with grade 3 dyspnea at baseline (according to CTCAE version 4.03)
Patients with Pancoast tumors
Prior radiotherapy treatment to the thorax
Any contraindications to the administration of thoracic radiotherapy
Pregnant women
Clareo Health | Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.
